BioVie Announces Positive Phase 2 SunRise-PD Trial for Parkinson's Drug Bezisterim
BioVie reported that the Phase 2 SUNRISE-PD trial of bezisterim was successful, showing significant improvements in motor and non-motor symptoms of early Parkinson's disease patients and a positive impact on biological markers of the disease. The positive clinical data create sig
View filing at SEC.gov →